(Q43919591)

English

Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation).

scientific article published in March 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 November 2017

Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation). (English)

1 reference

Europe PubMed Central

28 November 2017

0 references

hydrochlorothiazide

1 reference

based on heuristic

inferred from title

author name string

Syed T Rahman

1

1 reference

Europe PubMed Central

28 November 2017

Wright B Lauten

2

1 reference

Europe PubMed Central

28 November 2017

Qamar A Khan

3

1 reference

Europe PubMed Central

28 November 2017

Sushant Navalkar

4

1 reference

Europe PubMed Central

28 November 2017

Sampath Parthasarathy

5

1 reference

Europe PubMed Central

28 November 2017

Bobby V Khan

6

1 reference

Europe PubMed Central

28 November 2017

language of work or name

0 references

publication date

1 March 2002

1 reference

Europe PubMed Central

28 November 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

28 November 2017

89

1 reference

Europe PubMed Central

28 November 2017

6

1 reference

Europe PubMed Central

28 November 2017

686-690

1 reference

Europe PubMed Central

28 November 2017

Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902340-2

7 January 2021

Evaluation of serum levels of solubilized adhesion molecules and cytokine receptors in coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902340-2

7 January 2021

Maximally reducing cardiovascular risk in the treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902340-2

7 January 2021

Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902340-2

7 January 2021

Effects of in vitro addition of captopril on copper-induced low density lipoprotein oxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902340-2

7 January 2021

Lucigenin chemiluminescence in the assessment of neutrophil superoxide production

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902340-2

7 January 2021

Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902340-2

7 January 2021

Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902340-2

7 January 2021

Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902340-2

7 January 2021

Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902340-2

7 January 2021

Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902340-2

7 January 2021

Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902340-2

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902340-2

7 January 2021

Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902340-2

7 January 2021

Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902340-2

7 January 2021

Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902340-2

7 January 2021

Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902340-2

7 January 2021

Identifiers

10.1016/S0002-9149(01)02340-2

1 reference

Europe PubMed Central

28 November 2017

1 reference

Europe PubMed Central

28 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43919591&oldid=2104393151"